title: What next for preimplantation genetic screening? More randomized controlled trials needed?
abstract: The recent debate on preimplantation genetic screening (PGS) has raised questions about its routine use in clinical practice. It has been suggested that the most effective way to resolve the debate about the usefulness of PGS is to perform more well-designed and well-executed randomized controlled trials (RCTs). However, in view of the lack of evidence for the effectiveness of PGS and the accumulating evidence for its harmfulness, it is our opinion that it is unethical to perform additional RCTs for the indication advanced maternal age using cleavage stage biopsy.
authors.affiliation: Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. s.mastenbroek@amc.uva.nl
authors.forename: S
authors.initials: S
authors.lastname: Mastenbroek
authors.forename: P
authors.initials: P
authors.lastname: Scriven
authors.forename: M
authors.initials: M
authors.lastname: Twisk
authors.forename: S
authors.initials: S
authors.lastname: Viville
authors.forename: F
authors.initials: F
authors.lastname: Van der Veen
authors.forename: S
authors.initials: S
authors.lastname: Repping
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008423:Maternal Age; D011247:Pregnancy; D011256:Pregnancy Outcome; D019836:Preimplantation Diagnosis / Q000009:adverse effects / Q000941:ethics* / Q000639:trends; D016032:Randomized Controlled Trials as Topic